Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia

Schizophrenia Research

Volumn 113, Issue 2-3, 2009, Pages 246-251

  Edlinger, Monika ^a   Hofer, Alex ^a   Rettenbacher, Maria A ^a   Baumgartner, Susanne ^a   Widschwendter, Christian G ^a   Kemmler, G ^a   Neco, Nazanin Ahmadian ^a   Fleischhacker, W Wolfgang ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Antipsychotic drug; Choice; Decision; Schizophrenia; Treatment

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; OLANZAPINE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL;

ADULT; AGED; ARTICLE; BODY MASS; DIZZINESS; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; FEMALE; GYNECOMASTIA; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; RIGIDITY; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL ASPECT; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; DRUG UTILIZATION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68049120183     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.06.008     Document Type: Article

References (32)

1. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia (2008). http://www.psychiatryonline.com/pracGuide/pracGuideChapToc_6.aspx http://www.psychiatryonline.com/pracGuide/pracGuideChapToc_6.aspx. Accessed Sept. 15
2. Ayuso-Gutierrez J.L., and del Rio Vega J.M. Factors influencing relapse in the long-term course of schizophrenia. Schizophr. Res. 28 (1997) 199-206
3. Barbui C., et al. Determinants of first- and second-generation antipsychotic drug use in clinically unstable patients with schizophrenia treated in four European countries. Int. Clin. Psychopharmacol. 21 (2006) 73-79
4. Buis W. Patient's opinions concerning side effects of neuroleptics. Am. J. Psychiatry. 149 (1992) 844-845
5. Byerly M.J., et al. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophr. Res. 86 1-3 (2006) 244-250
6. Casey D. Side effect profiles of new antipsychotic agents. J. Clin. Psychiatry 57 (1996) 40-45
7. Covell N.H., et al. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr. Bull. 28 1 (2002) 17-29
8. Elkis H. Treatment-resistant schizophrenia. Psychiatr. Clin. North Am. 30 3 (2007) 511-533
9. Gaebel W., et al. Atypical and typical neuroleptics in acute schizophrenia and related delusional disorders (drug choice, switching and outcome under naturalistic treatment conditions). Eur. Arch. Psychiatry Clin. Neurosci. 253 (2003) 175-184
10. Gordon G., et al. Choice of atypical antipsychotic therapy for patients with schizophrenia: an analysis of a medicaid population. Curr. Therap. Res. 66 (2005) 463-474
11. Hamann J., et al. Medical decision making in antipsychotic drug choice for schizophrenia. Am. J. Psychiatry 161 (2004) 1301-1204
12. Hamann J., et al. How do psychiatrists choose among different antipsychotics?. Eur. J. Clin. Pharmacol. 61 (2005) 851-854
13. Hamann J., et al. Psychiatric decision making in the adoption of a new antipsychotic in Germany. Psychiatr. Serv. 57 (2006) 700-703
14. Hamann J., et al. Shared decision making for inpatients with schizophrenia. Acta Psychiatr. Scand. 114 (2006) 265-273
15. Hamann J., et al. Shared decision making and long-term outcome in schizophrenia treatment. J. Clin. Psychiatry 68 (2007) 992-997
16. Hoblyn J., et al. Factors in choosing atypical antipsychotics: toward understanding the bases of physicians' prescribing decisions. J. Psychiatr. Res. 40 (2006) 160-166
17. Kay S.R., et al. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
18. Lindenmayer J.P., et al. Five-factor model of schizophrenia. J. Nerv. Ment. Dis. 182 (1994) 631-638
19. Lindenmayer J.P., et al. Five factor model of schizophrenia: replication across samples. Schizophr. Res. 14 (1995) 229-234
20. Lingjaerde O., et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic treated patients. Acta Psychiatr. Scand. Suppl. 334 (1987) 1-100
21. Mortimer A. How do we choose between atypical antipsychotics? The advantages of amisulpride. Int. J. Neuropsychopharmacol. 7 Suppl 1 (2004) S1-S5
22. Motlová L., et al. Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?. Ann. Clin. Psychiatry 19 2 (2007) 133-143
23. Müller D.J., and Kennedy J.L. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 7 6 (2006) 863-887
24. National Institute for Clinical Excellence. Schizophrenia, Full national clinical guideline on core interventions in primary and secondary care (2008). http://www.nice.org.uk/page.aspx?o=42460 http://www.nice.org.uk/page.aspx?o=42460. Accessed Sept. 15
25. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 Suppl 1 (2005) 1-93
26. Opolka J.L., et al. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatr. Serv. 55 2 (2004) 151-156
27. Reynolds G.P., et al. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 29 6 (2005) 1021-1028
28. Sartorius N., et al. The usefulness and use of second-generation antipsychotic medications. Curr. Opin. Psychiatry 15 Suppl.1 (2002) S1-S51
29. Tandon R., et al. Section of Pharmacopsychiatry, World Psychiatric Association. World Psychiatric Association Pharmacopsychiatry Section. Schizophr. Res. 100 13 (2008) 20-38 Electronic publication 2008 Feb 19
30. Tschoner A., et al. Metabolic side effects of antipsychotic medication. Int. J. Clin. Pract. 61 8 (2007) 1356-1370
31. Svestka J., et al. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. Neuro Endocrinol. Lett. 28 6 (2007) 881-888
32. Watkins C., et al. Characteristics of general practitioners who frequently see drug industry representatives: national cross sectional study. BMJ 326 (2003) 1178-1179